{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:00:11Z","timestamp":1792821611432,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["#2019PG-CD024"],"award-info":[{"award-number":["#2019PG-CD024"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["# 3136\/22"],"award-info":[{"award-number":["# 3136\/22"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["#53233623"],"award-info":[{"award-number":["#53233623"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Janus kinase [JAK] inhibitors are used for treating inflammatory bowel diseases [IBD]. We aimed to identify the molecular effects of JAK inhibition in human intestinal mucosa, considering IBD location and phenotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Colonic and ileal explants from patients with ulcerative colitis [UC], Crohn\u2019s disease [CD], and non-IBD controls [NC] were assessed for levels of phosphorylated signal transducers and activators of transcription [p-STAT] and expression of inflammatory genes in response to an ex vivo JAK inhibitor [tofacitinib]. Cytokine production by lamina propria lymphocytes in response to tofacitinib was assessed. Human intestinal organoids were used to investigate the effects of JAK inhibitors on inducible nitric oxide synthase [iNOS] expression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Explants were collected from 68 patients [UC\u2005=\u200520, CD\u2005=\u200520, NC\u2005=\u200528]. p-STAT1\/3\/5 inhibition rates varied, being higher in colonic compared to ileal explants. p-STAT1\/3 inhibition rates negatively correlated with levels of C-reactive protein [CRP]. While significant alterations in 120 of 255 inflammatory genes were observed in colonic explants, only 30 were observed in ileal NC explants. In colonic explants from UC, significant alterations were observed in five genes, including NOS2. JAK inhibition significantly decreased Th1\/Th2\/Th17-related cytokine production from lamina propria lymphocytes. Various JAK inhibitors reduced the interferon-\u03b3-induced increase in iNOS expression in organoids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A site-specific anti-inflammatory effect of JAK inhibition by tofacitinib was noted, whereby the colon was more robustly affected than the ileum. The ex vivo response to tofacitinib is individual. JAK inhibition may attenuate inflammation by decreasing iNOS expression. Ex vivo mucosal platforms may be a valuable resource for studying personalized drug effects in patients with IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae117","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T15:39:11Z","timestamp":1722181151000},"source":"Crossref","is-referenced-by-count":8,"title":["Discordant Effects of Janus Kinase Inhibition <i>Ex Vivo<\/i> on Inflammatory Responses in Colonic Compared to Ileal Mucosa"],"prefix":"10.1093","volume":"19","author":[{"given":"Kawsar","family":"Kaboub","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Abu-Taha","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Arrouasse","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Shaham-Barda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Wasserberg","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]},{"name":"Department of Surgery, Beilinson Campus, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Hayman-Manzur","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beilinson Campus, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Friedenberg","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adva","family":"Levy-Barda","sequence":"additional","affiliation":[{"name":"Biobank, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-2840","authenticated-orcid":false,"given":"Idan","family":"Goren","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Levi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar","family":"Banai-Eran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avni-Biron","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E","family":"Ollech","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Sharar-Fischler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-5271","authenticated-orcid":false,"given":"Henit","family":"Yanai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Cohen-Kedar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren M","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah-Tikva ,","place":["Israel"]},{"name":"The Felsenstein Medical Research Center, Rabin Medical Center and Tel-Aviv University , Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"2025011304563131800_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2025011304563131800_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2025011304563131800_CIT0003","doi-asserted-by":"crossref","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025011304563131800_CIT0004","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.3390\/jcm11154374","article-title":"Novel therapies and approaches to inflammatory bowel disease (IBD)","volume":"11","author":"Furfaro","year":"2022","journal-title":"J Clin Med"},{"key":"2025011304563131800_CIT0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2025011304563131800_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025011304563131800_CIT0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025011304563131800_CIT0008","first-page":"287","article-title":"Janus kinases in immune cell signaling","volume":"273","author":"Laurence","year":"2009","journal-title":"Immunol Rev"},{"key":"2025011304563131800_CIT0009","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn\u2019 s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025011304563131800_CIT0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019 s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"2025011304563131800_CIT0011","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2025011304563131800_CIT0012","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"2025011304563131800_CIT0013","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","article-title":"Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett\u2019s epithelium","volume":"141","author":"Sato","year":"2011","journal-title":"Gastroenterology"},{"key":"2025011304563131800_CIT0014","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1002\/cpim.106","article-title":"Establishment and culture of human intestinal organoids derived from adult stem cells","volume":"130","author":"Pleguezuelos-Manzano","year":"2020","journal-title":"Curr Protoc Immunol"},{"key":"2025011304563131800_CIT0015","doi-asserted-by":"crossref","first-page":"22.6.1","DOI":"10.1002\/cptx.40","article-title":"Preparation of human primary colon tissue-derived organoid using air liquid interface culture","volume":"75","author":"Usui","year":"2018","journal-title":"Curr Protoc Toxicol"},{"key":"2025011304563131800_CIT0016","doi-asserted-by":"crossref","first-page":"G1630","DOI":"10.1152\/ajpgi.00294.2006","article-title":"Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-\u03b3","volume":"292","author":"Dotan","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025011304563131800_CIT0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.gastro.2012.12.001","article-title":"Transforming growth factor \u03b2 signaling controls activities of human intestinal CD8+ T suppressor cells","volume":"144","author":"Rabinowitz","year":"2013","journal-title":"Gastroenterology"},{"key":"2025011304563131800_CIT0018","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0016-5085(96)70055-0","article-title":"Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease","volume":"111","author":"Singer","year":"1996","journal-title":"Gastroenterology"},{"key":"2025011304563131800_CIT0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/gut.43.1.56","article-title":"Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines","volume":"43","author":"Kolios","year":"1998","journal-title":"Gut"},{"key":"2025011304563131800_CIT0020","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-2362.1996.tb02131.x","article-title":"Expression of nitric oxide synthase in ulcerative colitis","volume":"26","author":"Godkin","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"2025011304563131800_CIT0021","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025011304563131800_CIT0022","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ecco-jcc\/jjad212.0009","article-title":"OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn\u2019s Disease: Data from the PIZZICATO umbrella study","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0023","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025011304563131800_CIT0024","doi-asserted-by":"crossref","first-page":"G396","DOI":"10.1152\/ajpgi.00383.2020","article-title":"Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1\/3 reduction in T-cells","volume":"320","author":"Brand","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025011304563131800_CIT0025","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of Janus Kinase 1 inhibition with upadacitinib in the Crohn\u2019s disease intestinal mucosa: Analysis from the CELEST study","volume":"27","author":"Aguilar","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025011304563131800_CIT0026","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2025011304563131800_CIT0027","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0029","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025011304563131800_CIT0030","doi-asserted-by":"crossref","first-page":"100097","DOI":"10.1016\/j.crphar.2022.100097","article-title":"Ileal and colonic Crohn\u2019s disease: does location makes a difference in therapy efficacy","volume":"3","author":"Atreya","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2025011304563131800_CIT0031","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025011304563131800_CIT0032","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41575-021-00424-6","article-title":"Location is important: differentiation between ileal and colonic Crohn\u2019s disease","volume":"18","author":"Atreya","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025011304563131800_CIT0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312673","article-title":"Recent advances in clinical practice: a systematic review of isolated colonic Crohn\u2019s disease: the third IBD","volume":"66","author":"Subramanian","year":"2017","journal-title":"Gut"},{"key":"2025011304563131800_CIT0034","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.gastro.2023.03.234","article-title":"Filgotinib for the treatment of small bowel Crohn\u2019s disease: the DIVERGENCE 1 trial","volume":"165","author":"D\u2019Haens","year":"2023","journal-title":"Gastroenterology"},{"key":"2025011304563131800_CIT0035","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ibd\/izab311","article-title":"Meta-analysis of IBD gut samples gene expression identifies specific markers of ileal and colonic diseases","volume":"28","author":"Perez","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025011304563131800_CIT0036","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.3390\/ijms21186632","article-title":"Tofacitinib and baricitinib are taken up by different uptake mechanisms determining the efficacy of both drugs in RA","volume":"21","author":"Amrhein","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025011304563131800_CIT0037","doi-asserted-by":"crossref","article-title":"Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness","author":"Ku Jang","DOI":"10.1053\/j.gastro.2024.07.035"},{"key":"2025011304563131800_CIT0038","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/ecco-jcc\/jjab085","article-title":"Immunological networks defining the heterogeneity of inflammatory bowel diseases","volume":"15","author":"Selin","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0039","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/ecco-jcc\/jjab050","article-title":"Results of the seventh scientific workshop of ECCO: precision medicine in IBD-disease outcome and response to therapy","volume":"15","author":"Verstockt","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2025011304563131800_CIT0041","doi-asserted-by":"crossref","first-page":"1756283X1774502","DOI":"10.1177\/1756283X17745029","article-title":"Inflammatory bowel disease: towards a personalized medicine","volume":"11","author":"Flamant","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"2025011304563131800_CIT0042","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ibd\/izab278","article-title":"Predictors of sustained response with tofacitinib therapy in patients with ulcerative colitis","volume":"28","author":"Sandborn","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025011304563131800_CIT0043","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ecco-jcc\/jjaa162","article-title":"The JAK1\/3 inhibitor to tofacitinib suppresses t cell homing and activation in chronic intestinal inflammation","volume":"15","author":"Gerlach","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025011304563131800_CIT0044","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.3748\/wjg.v19.i25.3931","article-title":"Why interleukin-10 supplementation does not work in Crohn\u2019s disease patients","volume":"19","author":"Marlow","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025011304563131800_CIT0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3748\/wjg.v10.i5.620","article-title":"IL-10 and its related cytokines for treatment of inflammatory bowel disease","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"2025011304563131800_CIT0046","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1023\/A:1018849405922","article-title":"Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Kimura","year":"1997","journal-title":"Dig Dis Sci"},{"key":"2025011304563131800_CIT0047","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0140-6736(93)91476-3","article-title":"Nitric oxide synthase activity in ulcerative colitis and Crohn\u2019s disease","volume":"342","author":"Boughton-Smith","year":"1993","journal-title":"Lancet"},{"key":"2025011304563131800_CIT0048","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2567.2004.01984.x","article-title":"Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle","volume":"113","author":"Kolios","year":"2004","journal-title":"Immunology"},{"key":"2025011304563131800_CIT0049","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1074\/jbc.M609426200","article-title":"Essential role of the JAK\/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate","volume":"282","author":"Stempelj","year":"2007","journal-title":"J Biol Chem"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae117\/58840264\/jjae117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjae117\/58840264\/jjae117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjae117\/58840264\/jjae117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T04:56:51Z","timestamp":1736744211000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae117\/7723252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae117","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,29]]},"article-number":"jjae117"}}